Rescue PTCA following failed thrombolysis and primary PTCA: A retrospective study of angiographic and clinical outcome

被引：11

作者：

Bär F.W. ^{[1
,2
]}

Ophnis T.J.O. ^{[1
]}

Frederiks J. ^{[1
]}

De Swart H.B. ^{[1
]}

Van Ommen V.G. ^{[1
]}

De Zwaan C. ^{[1
]}

Vermeer F. ^{[1
]}

Gorgels A.P. ^{[1
]}

Wellens H.J. ^{[1
]}

机构：

[1] Department of Cardiology, Academic Hospital Maastricht, University of Limburg, Maastricht

[2] Department of Cardiology, Academic Hospital Maastricht, 6202 AZ Maastricht

来源：

Journal of Thrombosis and Thrombolysis | 1997年 / 4卷 / 2期

关键词：

Acute myocardial infarction; Primary PTCA; Rescue PTCA; Thrombolysis;

D O I：

10.1023/A:1008807321037

中图分类号：

学科分类号：

摘要：

Evidence is increasing that a patent culprit artery improves the prognosis of patients with acute myocardial infarction (AMI). Primary percutaneous transluminal coronary angioplasty (PTCA) has shown to be more effective than thrombolytic therapy alone. How effective is rescue PTCA after failed thrombolytic treatment? In a retrospective analysis, 176 consecutive patients with AMI and TIMI 0 or 1 perfusion grade were included. Patients had either rescue PTCA after failed thrombolysis (100 patients) or primary PTCA (76 patients). Angiographic data and in-hospital and 1-year outcome were analyzed. Comparison of baseline data of the two groups showed a higher proportion of long-standing angina and use of nitrates and aspirin in the primary PTCA group. Also, the delay between the onset of pain and PTCA was not significantly different, with a mean of 222 minutes for rescue PTCA and 245 minutes for primary PTCA (p = 0.52). The angiographic outcomes in the rescue PTCA group and the primary PTCA group were identical: The intervention was successful (TIMI 3 flow and residual stenosis < 50%) in 86.0% and 85.5%, respectively. Complication rates of the procedure were also similar, except for bleeding complications. Blood transfusion was only needed after rescue PTCA in 3.0% versus 0.0% in primary PTCA patients. Clinical outcomes during hospital stay in terms of death rate (4.0% and 6.6%), reinfarction (6.0% and 3.9%), recurrent angina (16.0% and 11.8%), and repeat interventions were comparable, as was the first-year outcome. Failed PTCA was the most important predictor of a poor 1-year outcome; 28.0% died after failed PTCA versus 4.6% after successful PTCA (p < 0.001). In this retrospective analysis of 176 AMI patients, angiographic and clinical outcome, including a 1-year follow-up in patients who had rescue PTCA after failed thrombolysis, were of the same magnitude of patients in whom primary PTCA was performed. These findings suggest that in this subset the outcome of patients with rescue PTCA because of failed thrombolysis is good and is comparable with patients who underwent primary PTCA.

引用

页码：281 / 288

页数：7

共 61 条

[1]

Lincoff A.M., Topol E.J., Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?, Circulation, 87, pp. 1792-1805, (1993)

[2]

Kennedy J.W., Ritchie J.L., Davis K.B., Fritz J.K., Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction, N Engl J Med, 309, pp. 1477-1482, (1983)

[3]

Simoom M.L., Serruys P.W., Van Den Brand M., Et al., Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival, J Am Coll Cardiol, 7, pp. 717-728, (1986)

[4]

Schroder R., Neuhaus K.-L., Leizorovicz A., Linderer T., Tebbe U., A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): Long-term mortality and morbidity, J Am Coll Cardiol, 9, pp. 197-203, (1987)

[5]

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Lancet, 1, pp. 397-402, (1986)

[6]

Wilcox R.G., Von Der Lippe G., Olsson C.G., Et al., Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET), Lancet, 2, pp. 525-530, (1988)

[7]

Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, 2, pp. 349-360, (1988)

[8]

Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial, Lancet, 1, pp. 545-549, (1988)

[9]

Topol E.J., Califf R.M., George B.S., Et al., A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction, N Engl J Med, 317, pp. 581-588, (1987)

[10]

Thrombolysis in Myocardial Infarction (TIMI) trial, N Engl J Med, 312, pp. 932-936, (1985)

← 1 2 3 4 5 6 7 →